It does seem strange they'd mention mid 2024, particularly when first patient dosed announcement was Jan 17 this year. Assuming at least a 3-4 month follow-up then they're predicting 26 enrolments in the space of a few months? Odd. Would have to be super quick enrolment. They did mention that historically Korea enrolment in pancreatic ca trials has been strong, but this seems a big stretch.
The Korea link is intriguing.
Ann: Quarterly Activities/Appendix 4C Cash Flow Report, page-47
-
- There are more pages in this discussion • 12 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
